Ocular Therapeutix, Inc.
OCUL
$6.93
-$0.07-1.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 59.65M | 63.72M | 61.44M | 61.10M | 59.84M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.65M | 63.72M | 61.44M | 61.10M | 59.84M |
| Cost of Revenue | 155.32M | 133.26M | 108.62M | 86.40M | 72.44M |
| Gross Profit | -95.67M | -69.54M | -47.18M | -25.31M | -12.59M |
| SG&A Expenses | 108.41M | 102.24M | 94.07M | 89.16M | 78.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 263.73M | 235.50M | 202.70M | 175.57M | 151.29M |
| Operating Income | -204.08M | -171.78M | -141.26M | -114.47M | -91.45M |
| Income Before Tax | -192.71M | -193.51M | -174.34M | -138.36M | -115.27M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -192.71 | -193.51 | -174.34 | -138.36 | -115.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -192.71M | -193.51M | -174.34M | -138.36M | -115.27M |
| EBIT | -204.08M | -171.78M | -141.26M | -114.47M | -91.45M |
| EBITDA | -200.23M | -167.99M | -137.46M | -110.75M | -88.03M |
| EPS Basic | -1.15 | -1.26 | -1.32 | -1.11 | -1.11 |
| Normalized Basic EPS | -0.72 | -0.66 | -0.69 | -0.67 | -0.67 |
| EPS Diluted | -1.15 | -1.26 | -1.32 | -1.35 | -1.36 |
| Normalized Diluted EPS | -0.72 | -0.66 | -0.69 | -0.66 | -0.66 |
| Average Basic Shares Outstanding | 670.23M | 632.86M | 549.27M | 461.65M | 373.87M |
| Average Diluted Shares Outstanding | 670.23M | 632.86M | 549.27M | 467.42M | 379.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |